Inspire Medical Systems, Inc. Announces Regulatory Approval of Inspire Therapy in Australia

Download as PDF

MINNEAPOLIS, MN – August 12, 2020 – Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a
medical technology company focused on the development and commercialization of innovative and
minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), today announced that the
Australian Therapeutic Goods Administration (“TGA”) has approved Inspire therapy to treat moderate to
severe OSA in patients who are unable to benefit from continuous positive airway pressure (“CPAP”).

Recent published data estimates that nearly 5% of Australian men and women are diagnosed with OSA.
Additional industry estimates indicate that approximately one million Australians have an Apnea
Hypopnea Index (“AHI”) greater than 15, which qualifies them as moderate or severe OSA patients.
“This approval for our Inspire therapy is the first step to providing patients and physicians in Australia with
a new alternative for the treatment of moderate to severe OSA,” said Tim Herbert, President and Chief
Executive Officer of Inspire Medical Systems. “Inspire therapy is supported by a strong and growing body
of clinical evidence demonstrating the safety and efficacy of our therapy. We look forward to completing
the reimbursement process in Australia and initiating our commercial activity.”

Concurrent with the regulatory review, Inspire has applied for reimbursement in Australia, and the
application is under review by the Medical Services Advisory Committee (“MSAC”), which is an
independent committee established by the Australian Government Minister for Health to evaluate new
medical services proposed for public funding. Inspire will continue with the active discussions with the
MSAC, including in-person meetings in late 2020. The reimbursement process is anticipated to be
completed during 2021 and Inspire expects to launch its therapy in Australia thereafter.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of
innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary
Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and
effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit

Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical
facts contained in this press release are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’
‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or
‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements include, but are not limited to, statements
concerning: our expected commercial launch of Inspire therapy, estimates regarding our market
opportunity in Australia and the timing of discussions involving and completion of the reimbursement
process in Australia. These forward-looking statements are based on management’s current expectations
and involve known and unknown risks and uncertainties that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such risks and uncertainties include, among
others, estimates regarding the annual total addressable market for our Inspire therapy in the United
States and our market opportunity outside the United States, future results of operations, financial
position, research and development costs, capital requirements and our needs for additional financing;
commercial success and market acceptance of our Inspire therapy, including in Australia; the impact of
the global COVID-19 pandemic; our ability to achieve and maintain adequate levels of coverage or
reimbursement for our Inspire system or any future products we may seek to commercialize; general and
international economic, political, and other risks, including currency and stock market
fluctuations and the uncertain economic environment; and our expectations about market trends. Other
important factors that could cause actual results, performance or achievements to differ materially from
those contemplated in this press release can be found under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2019, as updated in our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2020, and as such factors may be updated from time to time in
our other filings with the SEC, which are accessible on the SEC’s website at and the
Investors page of our website at These and other important factors could cause
actual results to differ materially from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent management’s estimates as of the date of
this press release. While we may elect to update such forward-looking statements at some point in the
future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events
cause our views to change. Thus, one should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such forward-looking statements. These forward-
looking statements should not be relied upon as representing our views as of any date subsequent to the
date of this press release.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
[email protected]